Viking Total Assets from 2010 to 2025

VKTX Stock

USD 28.95 0.60 2.12%

Viking Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2013-12-31

Previous Quarter

937.9 M

Current Value

908.3 M

Quarterly Volatility

261.2 M

Yuan Drop

Covid

Check Viking Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viking Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 319 K, Interest Expense of 75.2 K or Selling General Administrative of 51.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.23. Viking financial statements analysis is a perfect complement when working with Viking Therapeutics Valuation or Volatility modules.

Check out the analysis of Viking Therapeutics Correlation against competitors.

For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.

Latest Viking Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Viking Therapeutics over the last few years. Total assets refers to the total amount of Viking Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Viking Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Viking Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viking Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 908.32 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Viking Total Assets Regression Statistics

	Arithmetic Mean	219,291,874
	Geometric Mean	22,392,660
	Coefficient Of Variation	139.95
	Mean Deviation	219,733,351
	Median	168,529,000
	Standard Deviation	306,891,910
	Sample Variance	94182.6T
	Range	953.6M
	R-Value	0.81
	Mean Square Error	35004.5T
	R-Squared	0.65
	Significance	0.0002
	Slope	52,093,704
	Total Sum of Squares	1412739.7T

Viking Total Assets History

	2025	953.7 M
	2024	908.3 M
	2023	368.5 M
	2022	168.5 M
	2021	210.7 M
	2020	256.5 M
	2019	284.3 M

Other Fundumenentals of Viking Therapeutics

Intangibles To Total Assets

Viking Therapeutics Total Assets component correlations

	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Total Assets	Total Current Assets	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Deferred Long Term Liab	Short Long Term Debt	Short Term Investments	Long Term Debt Total	Capital Surpluse	Treasury Stock	Net Invested Capital	Net Working Capital	Capital Stock
Total Stockholder Equity		-0.56	-0.9	0.83	0.69	0.64	1.0	1.0	-0.17	0.56	-0.62	-0.51	0.5	1.0	-0.86	0.68	-0.15	1.0	1.0	-0.86
Net Debt	-0.56		0.79	-0.73	-0.56	-0.84	-0.57	-0.57	0.24	-0.68	0.77	0.61	-0.66	-0.52	0.22	-0.86	0.02	-0.55	-0.55	0.22
Retained Earnings	-0.9	0.79		-0.95	-0.81	-0.75	-0.9	-0.9	0.1	-0.55	0.73	0.63	-0.64	-0.88	0.7	-0.79	0.04	-0.89	-0.89	0.7
Accounts Payable	0.83	-0.73	-0.95		0.88	0.64	0.84	0.84	-0.08	0.43	-0.63	-0.53	0.53	0.81	-0.69	0.69	-0.06	0.83	0.83	-0.69
Total Liab	0.69	-0.56	-0.81	0.88		0.49	0.71	0.71	-0.01	0.29	-0.49	-0.42	0.41	0.69	-0.62	0.53	-0.06	0.7	0.7	-0.62
Common Stock	0.64	-0.84	-0.75	0.64	0.49		0.64	0.64	-0.2	0.93	-0.92	-0.75	0.84	0.6	-0.22	0.99	0.07	0.62	0.63	-0.22
Total Assets	1.0	-0.57	-0.9	0.84	0.71	0.64		1.0	-0.16	0.56	-0.62	-0.51	0.5	1.0	-0.86	0.68	-0.15	1.0	1.0	-0.86
Total Current Assets	1.0	-0.57	-0.9	0.84	0.71	0.64	1.0		-0.16	0.56	-0.62	-0.51	0.5	1.0	-0.86	0.68	-0.15	1.0	1.0	-0.86
Short Term Debt	-0.17	0.24	0.1	-0.08	-0.01	-0.2	-0.16	-0.16		-0.24	-0.12	-0.42	0.35	-0.17	0.03	-0.3	0.83	-0.18	-0.18	0.03
Net Tangible Assets	0.56	-0.68	-0.55	0.43	0.29	0.93	0.56	0.56	-0.24		-0.87	-0.7	0.75	0.52	-0.17	0.9	0.0	0.54	0.55	-0.17
Current Deferred Revenue	-0.62	0.77	0.73	-0.63	-0.49	-0.92	-0.62	-0.62	-0.12	-0.87		0.94	-0.94	-0.57	0.29	-0.88	-0.25	-0.6	-0.6	0.29
Deferred Long Term Liab	-0.51	0.61	0.63	-0.53	-0.42	-0.75	-0.51	-0.51	-0.42	-0.7	0.94		-0.96	-0.47	0.25	-0.7	-0.45	-0.49	-0.49	0.25
Short Long Term Debt	0.5	-0.66	-0.64	0.53	0.41	0.84	0.5	0.5	0.35	0.75	-0.94	-0.96		0.46	-0.16	0.78	0.51	0.48	0.48	-0.16
Short Term Investments	1.0	-0.52	-0.88	0.81	0.69	0.6	1.0	1.0	-0.17	0.52	-0.57	-0.47	0.46		-0.88	0.64	-0.17	1.0	1.0	-0.88
Long Term Debt Total	-0.86	0.22	0.7	-0.69	-0.62	-0.22	-0.86	-0.86	0.03	-0.17	0.29	0.25	-0.16	-0.88		-0.27	0.16	-0.87	-0.87	1.0
Capital Surpluse	0.68	-0.86	-0.79	0.69	0.53	0.99	0.68	0.68	-0.3	0.9	-0.88	-0.7	0.78	0.64	-0.27		-0.05	0.67	0.67	-0.27
Treasury Stock	-0.15	0.02	0.04	-0.06	-0.06	0.07	-0.15	-0.15	0.83	0.0	-0.25	-0.45	0.51	-0.17	0.16	-0.05		-0.17	-0.17	0.16
Net Invested Capital	1.0	-0.55	-0.89	0.83	0.7	0.62	1.0	1.0	-0.18	0.54	-0.6	-0.49	0.48	1.0	-0.87	0.67	-0.17		1.0	-0.87
Net Working Capital	1.0	-0.55	-0.89	0.83	0.7	0.63	1.0	1.0	-0.18	0.55	-0.6	-0.49	0.48	1.0	-0.87	0.67	-0.17	1.0		-0.87
Capital Stock	-0.86	0.22	0.7	-0.69	-0.62	-0.22	-0.86	-0.86	0.03	-0.17	0.29	0.25	-0.16	-0.88	1.0	-0.27	0.16	-0.87	-0.87

Click cells to compare fundamentals

About Viking Therapeutics Financial Statements

Viking Therapeutics investors use historical fundamental indicators, such as Viking Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viking Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	908.3 M	953.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Viking Stock Analysis

When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC